Day: January 31, 2024

Eargo will provide customers with even more over-the-counter (OTC) choices to help address hearing loss on their own termsEargo SEMSRP $1,650LINK By EargoMSRP $799SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand’s portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights...

NAPANEE, Ontario, Jan. 31, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”, or the “Company”) (CSE:MESC) is thrilled to provide further insights into the accomplishments of its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. The subsidiary has achieved a noteworthy milestone in the cultivation and ethical distribution of psychoactive plants and is delighted to announce the formalization of product release specifications for both fresh and dried peyote (Lophophora williamsii). This significant development underscores our unwavering commitment to quality, consistency, and ethical practices in the cultivation and distribution of peyote. Stringent Quality Standards: The product release specifications establish rigorous quality standards, guaranteeing that both fresh and dried peyote consistently...

Lower your operational costs for retail, wholesale and eCommerce fulfillment: Achieve 2X performance per sq ft, with a high-volume AI-driven solution built to operate reliably in the toughest warehouse environments. BEDFORD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Berkshire Grey, Inc., a leader in AI-enabled robotic solutions that automate supply chain processes, is excited to announce the latest and 4th generation of their BG Robotic Sortation solution. This latest version of the solution integrates cutting-edge engineering and insights derived from nearly a decade’s worth of warehouse production picks, representing the next generation of order processing and fulfillment in the industry. With businesses facing increased challenges around labor shortages and escalating space constraints, the BG Robotic Sortation solution (BG RPS/RSPS)...

—New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity for adoptive cell therapy and may result in a more effective cell therapy for hematological malignancies will be presented at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024. Presentation Details are as follows:Title: Enhancing NK cell cytotoxicity against...

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 10:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that...

MINNEAPOLIS, MN, US, Jan. 31, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of a collagen-elastin hydrogel microparticulate biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the joints of dogs. “We were pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of this veterinary medical device when injected into the joints of dogs,”...

23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector functionPhase 1 clinical study in patients with solid tumors to commence in H1 2024The target for ‘1473 was discovered through 23andMe’s proprietary research platform, the world’s largest recontactable database of de-identified human genetic and phenotypic informationSOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application for...